CareFusion Will Expand IV Infusion Portfolio With $225 Mil. Medegen Buy
This article was originally published in The Gray Sheet
Executive Summary
CareFusion says its planned $225 million acquisition of needleless intravenous infusion device maker Medegen will improve its ability to compete on claims of reducing hospital-acquired infections
You may also be interested in...
CareFusion: Increased Infusion Sales Offset By Light Flu Season
CareFusion had mixed results last quarter, combining increased infusion pump sales offset by reduced respiratory revenues, due, in part, to a lighter flu season, the firm said Nov. 2.
CareFusion: Increased Infusion Sales Offset By Light Flu Season
CareFusion had mixed results last quarter, combining increased infusion pump sales offset by reduced respiratory revenues, due, in part, to a lighter flu season, the firm said Nov. 2.
CareFusion Aims To Accelerate Infusion Sales Growth Post Baxter Recall
CareFusion expects to grow infusion system sales at a brisk rate in fiscal 2011, in part by capitalizing on Baxter's ongoing infusion pump recall, the firm said during its Aug. 10 earnings call